Title : Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.

Pub. Date : 2021 Jan 28

PMID : 33068701






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here, we demonstrated that the BCL-XL targeting agent, ABT-263, increased intracellular ROS levels and targeting antioxidant pathways augmented the therapeutic efficacy of this BH3 mimetic. BH 3 BCL2 like 1 Homo sapiens